A Phase IV, Open Label Study in Healthy Male Subjects to Investigate the Extent of Maraviroc Exposure in Blood, Saliva, Seminal Fluid, and Rectal Mucosal Tissue Following Single and Multiple Dosing of Maraviroc.
Phase of Trial: Phase I
Latest Information Update: 12 May 2011
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- 12 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Feb 2010 Actual patient number (14) added as reported by ClinicalTrials.gov.
- 05 Feb 2010 Planned end date changed from 1 Jun 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov.